Symbols / SNGX Stock $1.25 +1.63%

Asset: Stock

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Rare disease drug for painful Behçet's ulcers gets key EU backing - Stock Titan hu, 26 Feb 2026 08
• Soligenix Announces Pricing of $7.5 Million Public Offering - PR Newswire Fri, 26 Sep 2025 07
• $SNGX stock is down 20% today. Here's what we see in our data. - Quiver Quantitative Wed, 17 Dec 2025 08
• Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance Wed, 20 Aug 2025 07
• Soligenix stock tumbles after pricing $7.5 million public offering - Investing.com Fri, 26 Sep 2025 07
• Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - The Globe and Mail hu, 05 Mar 2026 21
• Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely - simplywall.st Wed, 20 Aug 2025 07
• Why Is Soligenix Stock (SNGX) Up 50% Today? - TipRanks hu, 31 Jul 2025 07
• SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Research Tree hu, 12 Mar 2026 23
• Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog - RagingBull Mon, 18 Aug 2025 07
• Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone - Quiver Quantitative ue, 07 Oct 2025 07
• Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial - Yahoo Finance hu, 31 Jul 2025 07
• Miami BIO summit to feature Soligenix CEO on rare disease drugs - Stock Titan ue, 24 Feb 2026 08
• Soligenix stock rises after positive Behçet’s Disease treatment data - Investing.com hu, 18 Dec 2025 08
• Soligenix receives Nasdaq notice for non-compliance with equity listing rule - Investing.com Fri, 15 Aug 2025 07

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 8-K2026-02-12 View
• 8-K2026-01-23 View
• 42025-12-12 View
• 42025-12-12 View
• 42025-12-12 View
• 42025-12-12 View
• 8-K2025-11-18 View
• 10-Q2025-11-07 View
• 42025-10-03 View
• 8-K2025-09-29 View
• 8-K2025-08-18 View
• 8-K2025-08-15 View
• 10-Q2025-08-14 View
• 8-K2025-07-31 View
• 42025-06-20 View